Phaseline

Companies › Prime Gene Therapeutics

Prime Gene Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PG-011 Gel–Phase 3Atopic Dermatitis–
PG-033–Phase 1Lichen Simplex ChronicusDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06587685PG-011 GelPhase 3Atopic DermatitisImmunologyNov 2024
NCT07013097PG-033Phase 1Lichen Simplex ChronicusImmunologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Hangzhou Highlightll Pharmaceutical Paradigm Biopharmaceuticals Sagimet Biosciences BioCryst Pharmaceuticals Arthrosi Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.